Biogen has paused or canceled investment in the "majority" of the research programs it acquired when it bought Apellis Pharmaceuticals for $5.6 billion, according to Endpoints News.
A Biogen spokesperson told Endpoints that the company has also laid off "a small number" of employees from the acquired biotech.
The move is notable because companies typically pursue large acquisitions like this one partly to gain access to a target's pipeline — the portfolio of experimental drugs and research programs that could become future products. Shutting down most of that work so soon after closing the deal suggests Biogen valued specific assets far more than the broader research effort that came along with them.
The details available so far are limited. Endpoints reports the cuts cover the "majority" of Apellis's research programs and that the layoffs affected only a "small number" of staff, attributing both characterizations to a Biogen spokesperson. The source item does not specify which programs were halted, how many jobs were eliminated, or what Biogen plans to prioritize from the acquisition going forward.
Why it matters: When a large drugmaker pays billions for a smaller biotech and then quickly winds down most of its research, it signals that the deal was about a narrow set of prized assets rather than the company's full scientific output — a reminder that pipeline science acquired in big pharma deals can be cut as fast as it is bought.